Skip to main content
Fig. 3 | BMC Health Services Research

Fig. 3

From: Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

Fig. 3

Cost-effectiveness plane: A comparison of incremental costs, incremental QALYs, and ICERs between the standard of care (SoC) and new treatments using bDMARDs, tsDMARDS, and bsDMARDs in combination with MTX. QALYs: quality-adjusted life years, ICERs: incremental cost-effectiveness ratios, bDMARD: biologic disease-modifying antirheumatic drug, tsDMARD: targeted synthetic disease-modifying antirheumatic drug, SoC: Standard of care, MTX: Methotrexate, ETA: Etanercept (Enbrel®), IFX: Infliximab (Remicade®), GOL: Golimumab (Simponi®), TCZ: Tocilizumab (Actemra®), RTX: Rituximab (Mabthera®), TOF: Tofacitinib (Xeljanz®), BAR: Baricitinib (Olumiant®), bsIFXr: Biosimilar infliximab (Remsima®), bsIFXi: Biosimilar infliximab (Ixifi®), bsADA: Biosimilar adalimumab (Amgevita®), bsRTX: Biosimilar rituximab (Truxima®)

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us